TIGIT+ Tregs are increased in teclistamab nonresponders. T-cell gating of the CD4⁺ subpopulation identifies CD25⁺CD127^lo Tregs in (A) teclistamab nonresponders and (B) teclistamab responders. Values shown in panels A and B refer to percentage of total T cells, whereas contour plots refer to percentage of total CD4⁺ T cells. (C) CD4⁺ central memory T cells and (D) Treg abundance in teclistamab nonresponders vs responders. (E) Feature plots highlighting the differential expression of TIGIT, PD1, CTLA4, LAG3, TIM3, and CD38 by CD4⁺ TCM and Treg subpopulations.